Phase 1-2 Trial of antisense oligonucleotide tofersen for SOD1 ALS

T. Miller, M. Cudkowicz, P. J. Shaw, P. M. Andersen, N. Atassi, R. C. Bucelli, A. Genge, J. Glass, S. Ladha, A. L. Ludolph, N. J. Maragakis, C. J. McDermott, A. Pestronk, J. Ravits, F. Salachas, R. Trudell, P. Van Damme, L. Zinman, C. F. Bennett, R. LaneA. Sandrock, H. Runz, D. Graham, H. Houshyar, A. McCampbell, I. Nestorov, I. Chang, M. McNeill, L. Fanning, S. Fradette, T. A. Ferguson

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1-2 Trial of antisense oligonucleotide tofersen for SOD1 ALS'. Together they form a unique fingerprint.

Medicine & Life Sciences